A 52-week, randomised, double-blind, parallel-group, multi-centre, phase IIIB study comparing the long term safety of SYMBICORTO pMDI 160/4.5 mg x 2 actuations twice daily to budesonide HFA pMDI 160 mg x 2 actuations twice daily in adult/adolescent (greater than or equal to12 years) African American subjects with asthma.
Phase of Trial: Phase III
Latest Information Update: 29 Oct 2012
At a glance
- Drugs Budesonide/formoterol (Primary) ; Budesonide
- Indications Asthma
- Focus Adverse reactions
- Sponsors AstraZeneca
- 10 May 2012 Results from this trial published in the Journal of Allergy & Clinical Immunology in May 2012, according to an AstraZeneca media release. Top-line tolerability results were reported also in the media release.
- 06 Mar 2012 Long-term cardiovascular safety results presented at the 68th Annual Meeting of the American Academy of Allergy, Asthma and Immunology.
- 27 Oct 2011 Results presented at the 77th Annual Meeting of the American College of Chest Physicians: Chest 2011.
Most Recent Events
Table of Contents
- At a glance
- Trial Overview
- Trial Details
- Trial Centres
- Trial History